glucagon has been researched along with insulin glargine in 10 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (insulin glargine) | Trials (insulin glargine) | Recent Studies (post-2010) (insulin glargine) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 2,184 | 772 | 1,350 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Askari, H; Dagogo-Jack, S; Kim, B; Lehner, LL; Morrill, B; Sha, X | 1 |
| Bohannon, NJ | 1 |
| Floyd, C; Harmon, C; Willoughby, DF | 1 |
| Hauner, H; Holle, R; Kohlmann, T; Landgraf, W; Pirk, O; Scholten, T | 1 |
| Briscoe, VJ; Davis, SN; Gogitidze Joy, N; Hedrington, MS; Nicholson, W; Richardson, MA; Tate, DB; Wang, Z; Younk, L | 1 |
| Andreoli, AM; Bolli, GB; Candeloro, P; Cioli, P; Fanelli, CG; Lucidi, P; Marzotti, S; Porcellati, F; Schmidt, R | 1 |
| Campbell, MD; Gonzalez, JT; Rumbold, PL; Shaw, JA; Stevenson, EJ; Walker, M; West, DJ | 1 |
| Trautmann, ME; Vora, J | 1 |
| Bolli, GB; Candeloro, P; Cioli, P; Fanelli, CG; Lucidi, P; Marinelli Andreoli, A; Porcellati, F | 1 |
| Erdmann, S; Kahle-Stephan, M; Kapitza, C; Meier, JJ; Menge, BA; Nauck, MA; Schenker, N; Schliess, F | 1 |
2 review(s) available for glucagon and insulin glargine
| Article | Year |
|---|---|
A lesson in early morning hyperglycemia.
Topics: Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Complications; Dose-Response Relationship, Drug; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Somatomedins; Time Factors | 2004 |
Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Peptides; Postprandial Period; Treatment Outcome | 2018 |
5 trial(s) available for glucagon and insulin glargine
| Article | Year |
|---|---|
Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine.
Topics: Adult; Blood Glucose; Blood Pressure; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Heart Rate; Human Growth Hormone; Humans; Hydrocortisone; Hyperinsulinism; Hypoglycemia; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Norepinephrine; Recombinant Proteins; Reference Values | 2000 |
Dose-response effects of insulin glargine in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged | 2010 |
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.
Topics: Aged; Blood Glucose; Chromatography, Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Glucagon; Glucose Clamp Technique; Glycemic Index; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Middle Aged; Tandem Mass Spectrometry | 2014 |
Comparison of appetite responses to high- and low-glycemic index postexercise meals under matched insulinemia and fiber in type 1 diabetes.
Topics: Adult; Appetite Regulation; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 1; Diet, Diabetic; Dietary Fiber; Drug Therapy, Combination; Exercise; Glucagon; Glucagon-Like Peptide 1; Glycemic Index; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Jogging; Male; Meals; Postprandial Period | 2015 |
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Meals; Peptides; Postprandial Period | 2020 |
3 other study(ies) available for glucagon and insulin glargine
| Article | Year |
|---|---|
Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting | 2003 |
[Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Topics: Aged; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Costs; Female; Germany; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Needles; Patient Satisfaction; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2009 |
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Glucagon; Humans; Hypoglycemic Agents; Insulin Glargine; Lipolysis; Middle Aged | 2020 |